Multicenter, retrospective, real-word study of Multiple Sclerosis patients who started or switched to ocrelizumab
Latest Information Update: 21 Aug 2022
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 21 Aug 2022 New trial record
- 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology